ReviewCNS oncology2017
Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.
Review in CNS oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases.BMC cancer · 2023Trial
- Effect of combining targeted therapies or chemotherapy with stereotactic radiosurgery (SRS) on the prognosis of patients with brain metastases from non-small cell lung cancer (NSCLC).Journal of neuro-oncology · 2025Article
- Plant-derived exosome-like nanovesicles: mechanisms and molecular understanding in neurological disorders with potential therapeutic applications.Drug delivery and translational research · 2025Review
- Developing a predictive model and uncovering immune influences on prognosis for brain metastasis from lung carcinomas.Frontiers in oncology · 2025Article
- Cystic Brain Metastasis Outcomes After Gamma Knife Radiation Therapy.Advances in radiation oncology · 2024Article
- A comprehensive profiling of the immune microenvironment of breast cancer brain metastases.Neuro-oncology · 2022Article
- Surgery for brain metastases-impact of the extent of resection.Acta neurochirurgica · 2022Review
- The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine.Frontiers in oncology · 2022Article
- Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?Pharmaceutics · 2020Review
- Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer.Oncology letters · 2019Article
- Organotropism: new insights into molecular mechanisms of breast cancer metastasis.NPJ precision oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases (BM) continue to represent an unmet clinical need in oncology. Immunotherapy and targeted therapy hold great promise in the treatment of BM. Emerging data are confirming the activity of these agents in patients with BM. Genomic studies have confirmed that clinically actionable mutations are present in BM and they can be used in clinical studies to link targeted therapies with their genetic targets. Furthermore, as molecular signatures associated with sensitivity and resistance to immunotherapies are developed, we will better be able to select BM patients who will most benefit from these therapies. Understanding the genetic and immune evolution within BM should drive the next generation of immunotherapy and target therapy, as well as increase the accuracy of the selection process for these therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.